BIOTRONIK has received European clearance for the Lumax 740 series implantable defibrillators that have been confirmed to be MR-compatible when proper precautions are taken. The series is designed to work in tandem with BIOTRONIK’S Home Monitoring technology that can wirelessly transmit critical diagnostic data from the implant to the patient’s physician or monitoring center.
BIOTRONIK is reporting that following the approval, initial implantations of the devices were performed.
From the announcement:
The new Lumax 740 series is part of BIOTRONIK´s technologically advanced tachycardia product portfolio, which includes three ICDs, one CRT-D device and 16 leads. The Linoxsmart ICD leads have been proven over time to be of the highest quality and reliability, and are now further enhanced with ProMRI® compatibility. Besides featuring ProMRI® technology, the devices also stand out in the industry by providing longevities of up to 11 years.
Additionally, the intracardiac impedance measure is being used to investigate changes in left ventricular volume as a parameter that could potentially be taken for optimizing cardiac resynchronization therapy (CRT) and predicting worsening heart failure. This data is transmitted from the patient’s device to the physician continuously and automatically using BIOTRONIK Home Monitoring®, the industry’s only remote patient management system FDA- and CE-approved for the early detection of clinically relevant events.
Press release: BIOTRONIK Introduces the World’s First and Only Implantable Defibrillators Eligible for Magnetic Resonance Imaging …